Australia praised after rejecting biologic suffix

Adecision by Australia’s Therapeutic Goods Administration (TGA) to not use specific identifier suffixes as part of naming conventions for biologics has been welcomed by the global generics and biosimilars industry. Following a stakeholder consultation, the TGA said it had decided to “maintain the existing naming convention for biological and biosimilar medicines – that is continue using the Australian biological name, without a specific identifier suffix – and strengthen our adverse event reporting”.

Adecision by Australia’s Therapeutic Goods Administration (TGA) to not use specific identifier suffixes as part of naming conventions for biologics has been welcomed by the global generics and biosimilars industry. Following a stakeholder consultation, the TGA said it had decided to “maintain the existing naming convention for biological and biosimilar medicines – that is continue using the Australian biological name, without a specific identifier suffix – and strengthen our adverse event reporting”.

The TGA said it had made its decision in response to “broad stakeholder support for additional mechanisms to collect information...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Generics Bulletin